Healthcare provider profile · identity verified

Danka Samardzic, M.D.

Internal Medicine · CHELMSFORD, MA · NPI 1942268438

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	394	114
Atorvastatin Calcium	Atorvastatin Calcium	389	107
Simvastatin	Simvastatin	376	103
Amlodipine Besylate	Amlodipine Besylate	310	89
Omeprazole	Omeprazole	275	82
Levothyroxine Sodium	Levothyroxine Sodium	252	66
Losartan Potassium	Losartan Potassium	202	55
Metoprolol Succinate	Metoprolol Succinate	194	57
Metformin Hcl Er	Metformin Hcl	193	51
Gabapentin	Gabapentin	181	47
Trazodone Hcl	Trazodone Hcl	153	36
Lorazepam	Lorazepam	124	28
Furosemide	Furosemide	122	32
Albuterol Sulfate Hfa	Albuterol Sulfate	121	51
Citalopram Hbr	Citalopram Hydrobromide	121	31
Clonazepam	Clonazepam	111	15
Hydrochlorothiazide	Hydrochlorothiazide	106	33
Sertraline Hcl	Sertraline Hcl	101	30
Atenolol	Atenolol	90	26
Pravastatin Sodium	Pravastatin Sodium	90	19
Pantoprazole Sodium	Pantoprazole Sodium	85	18
Eliquis	Apixaban	82	17
Jardiance	Empagliflozin	80	20
Trulicity	Dulaglutide	80	13
Fluticasone Propionate	Fluticasone Propionate	79	22
Carvedilol	Carvedilol	73	17
Metformin Hcl	Metformin Hcl	69	22
Ozempic	Semaglutide	68	15
Clopidogrel	Clopidogrel Bisulfate	66	16
Alprazolam	Alprazolam	61	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	60	suppressed
Allopurinol	Allopurinol	57	13
Chlorthalidone	Chlorthalidone	57	17
Metoprolol Tartrate	Metoprolol Tartrate	53	14
Tamsulosin Hcl	Tamsulosin Hcl	50	17
Donepezil Hcl	Donepezil Hcl	49	suppressed
Famotidine	Famotidine	49	20
Glimepiride	Glimepiride	49	12
Duloxetine Hcl	Duloxetine Hcl	48	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	47	15
Finasteride	Finasteride	46	11
Rosuvastatin Calcium	Rosuvastatin Calcium	46	17
Oxycodone Hcl	Oxycodone Hcl	45	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	11
Tizanidine Hcl	Tizanidine Hcl	41	11
Fluoxetine Hcl	Fluoxetine Hcl	38	14
Montelukast Sodium	Montelukast Sodium	38	suppressed
Alendronate Sodium	Alendronate Sodium	37	14
Pregabalin	Pregabalin	36	suppressed
Tramadol Hcl	Tramadol Hcl	36	suppressed
Spironolactone	Spironolactone	35	suppressed
Meloxicam	Meloxicam	34	12
Prednisone	Prednisone	34	suppressed
Januvia	Sitagliptin Phosphate	33	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Diclofenac Sodium	Diclofenac Sodium	31	suppressed
Ondansetron Hcl	Ondansetron Hcl	31	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	suppressed
Lidocaine	Lidocaine	30	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	30	suppressed
Diazepam	Diazepam	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	15
Warfarin Sodium	Warfarin Sodium	28	11
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Enalapril Maleate	Enalapril Maleate	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Ezetimibe	Ezetimibe	26	suppressed
Lovastatin	Lovastatin	26	suppressed
Naproxen	Naproxen	25	suppressed
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Incruse Ellipta	Umeclidinium Bromide	24	suppressed
Ketoconazole	Ketoconazole	24	17
Nifedipine Er	Nifedipine	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Celecoxib	Celecoxib	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Temazepam	Temazepam	21	suppressed
Torsemide	Torsemide	21	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	13
Ibuprofen	Ibuprofen	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Mounjaro	Tirzepatide	18	suppressed
Norethindron-Ethinyl Estradiol	Norethindrone Ac/Eth Estradiol	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Labetalol Hcl	Labetalol Hcl	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Colchicine	Colchicine	15	suppressed
Fluocinonide	Fluocinonide	15	suppressed
Gemfibrozil	Gemfibrozil	15	suppressed
Midodrine Hcl	Midodrine Hcl	15	suppressed
Nystatin	Nystatin	15	suppressed
Eszopiclone	Eszopiclone	14	suppressed
Glipizide Er	Glipizide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	11
Unifine Pentips	Pen Needle, Diabetic	14	suppressed
Emgality Pen	Galcanezumab-Gnlm	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Carvedilol Er	Carvedilol Phosphate	12	suppressed
Humulin N	Insulin Nph Human Isophane	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Oxycontin	Oxycodone Hcl	12	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	11	11
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error